Current Evidence and Future Directions of Berberine Intervention in Depression

Zhu, Wenyao; Wu, Huiying; Sun, Zhihui; Guo, Yi Ming; Ge, Tongtong; Li, Bing-Jin; Li, Xin; Cui, Ranji

doi:10.3389/fphar.2022.824420

Cited by 9 publications

(7 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Berberine is an ammonium salt of alkaloid found in various plants such as Berberidacea, Coptis, and Hydrastis. Berberine has promising therapeutic effects on CVDs including atherosclerosis, myocardial infarction heart failure, cardiac hypertrophy, and hypertension [ 260 , 286 ] and could be a natural compound useful in the treatment of depression [ 287 ].…”

Section: Consequence Of Nox Inhibitors On Thrombosis and Depressionmentioning

confidence: 99%

NADPH-oxidases as potential pharmacological targets for thrombosis and depression comorbidity

Amadio,

Sandrini,

Zarà

et al. 2024

Redox Biology

View full text Add to dashboard Cite

Section: Consequence Of Nox Inhibitors On Thrombosis and Depressionmentioning

confidence: 99%

NADPH-oxidases as potential pharmacological targets for thrombosis and depression comorbidity

Amadio,

Sandrini,

Zarà

et al. 2024

Redox Biology

View full text Add to dashboard Cite

“…В нескольких других систематических обзорах было показано, что берберин обладает мощными анксиолитическими и антидепрессивными свойствами, и что он может быть эффективен и безопасен как в монотерапии лёгких и средних депрессий, так и в качестве адъюванта (потенцирующего агента) к АД [16,59].…”

Section: антоцианы из различных ягод а также из цветков гибискуса и к...unclassified

Plant Pigments in Psychiatry and Neurology: Historical and Modern Uses. Part Ii. A Literature Review With a Clinical Case Presentation

Bekker,

Bykov

2023

SJLSA

View full text Add to dashboard Cite

Purpose. To continue the narrative that we have started in the first part of this article, telling the reader about the history of the use of certain plant pigments in the treatment of several mental and neurological diseases, as well as in histological studies of brain tissue. To present to the reader the modern research data regarding the potential effectiveness and safety of some plant pigments in the treatment of various mental and psychosomatic pathologies, as well as some neurodegenerative diseases. Then, to present the reader a detailed description of a clinical case from the authors’ own practice. In the aforementioned case, the combined use of a low-calorie diet, exercise, metformin, chromium picolinate, thermogenic fat burners (caffeine and synephrine) and several different plant pigments and antioxidants — made it possible to achieve remission, both in terms of the mental state and in terms of endocrine and metabolic status in a young woman with obesity, polycystic ovary syndrome, depression, hyperuricemia, and an initial stage of urate-based urolithiasis, without the use of traditional psychopharmacotherapy. Methodology. For the purpose of second part of this review, we have selected primarily those plant pigments that are widely distributed in a variety of plants, and therefore cannot be attributed to any one plant (for example, the carotenoids lycopene, lutein and zeaxanthin, or anthocyanins, which are present in many berries and in the brightly colored flowers of some plants, such as hibiscus). Secondly, we were interested in the pigments from dyeing plants that some traditional medical systems (for example, traditional Chinese medicine, or Indian Ayurvedic medicine, or traditional medicine of the American Indians) have historically used and/or still continue using for the treatment of mental and neurological diseases. Many of those plants, for example, madder, are relatively little known as medicinal plants to modern European doctors and patients. We then searched for information about the medical use of such plant pigments with the help of search engines and databases such as PubMed, Google Scholar, Science Direct, Web of Science. Then we have summarized the data we had found and collected, and presented the summarized data in this second part of the review. Then we described in detail a clinical case from our own clinical practice. Results. The data we have obtained in the process of compiling this review, in our opinion, indicate a significant therapeutic potential for the use of some plant pigments that we have reviewed there — in the treatment of several mental and neurological disorders. The evidence base for the use of such plant pigments in psychiatry and neurology — varies widely in quality. For some plant pigments (eg, for lycopene from tomatoes, for lutein and zeaxanthin, for anthocyanins from various berries or from hibiscus flowers, for resveratrol from red wine and from dark grape varieties) — there are positive data from small randomized clinical trials, in combination with data from population studies (for example, on the association between the consumption of tomatoes, of lycopene and of carotenoids in general, of resveratrol and of plant antioxidants in general — and the frequency of depressive and anxiety disorders). For some other plant pigments that were historically used and are still used in some traditional medical systems, among other their uses, specifically for the treatment of mental and neurological disorders — for example, madder extract — we so far were able to find only experimental data on animals and on neuronal cell cultures, combined with the empirical experience of such traditional medical systems. Practical implications. The results that we have presented in this review, in our opinion, can provide theoretical and practical grounds for the use of some of the plant pigments that we have reviewed there (for example, lycopene, lutein and zeaxanthin, resveratrol, etc.) in the combination treatment of chronic fatigue syndrome, of mild forms of anxiety and depressive disorders, mild cognitive impairment — especially in patients who refuse standard psychopharmacotherapy, or who do not tolerate it well. Some other plant pigments that were historically used in the treatment of mental and neurological disorders in some traditional medical systems (for example, madder extract) — in our opinion, deserve to be studied in humans in this role, preferably in the format of randomized controlled trials.

show abstract

“…Berberine is a quaternary ammonium alkaloid biologically active ingredient extracted from Coptis chinensis with low toxicity and side effects. Berberine can reverse and improve the physiological changes caused by depression, such as monoamine neurotransmitter and dopamine levels, neuronal plasticity, and inflammatory responses [ 187 , 188 ]. Berberine has poor oral absorption, obvious intestinal first-pass metabolism, and limited absolute bioavailability [ 189 ].…”

Section: Intranasal Administration Of Antidepressant Active Ingredientsmentioning

confidence: 99%

Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients

et al. 2022

View full text Add to dashboard Cite

As a mental disease in modern society, depression shows an increasing occurrence, with low cure rate and high recurrence rate. It has become the most disabling disease in the world. At present, the treatment of depression is mainly based on drug therapy combined with psychological therapy, physical therapy, and other adjuvant therapy methods. Antidepressants are primarily administered peripherally (oral and intravenous) and have a slow onset of action. Antidepressant active ingredients, such as neuropeptides, natural active ingredients, and some chemical agents, are limited by factors such as the blood–brain barrier (BBB), first-pass metabolism, and extensive adverse effects caused by systemic administration. The potential anatomical link between the non-invasive nose–brain pathway and the lesion site of depression may provide a more attractive option for the delivery of antidepressant active ingredients. The purpose of this article is to describe the specific link between intranasal administration and depression, the challenges of intranasal administration, as well as studies of intranasal administration of antidepressant active ingredients.

show abstract

Current Evidence and Future Directions of Berberine Intervention in Depression

Cited by 9 publications

References 60 publications

NADPH-oxidases as potential pharmacological targets for thrombosis and depression comorbidity

NADPH-oxidases as potential pharmacological targets for thrombosis and depression comorbidity

Plant Pigments in Psychiatry and Neurology: Historical and Modern Uses. Part Ii. A Literature Review With a Clinical Case Presentation

Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients

Contact Info

Product

Resources

About